PEComa - Epidemiology Forecast - 2036

Perivascular Epithelioid Cell Neoplasm (PEComa) Insights and Trends

• Perivascular epithelioid cell neoplasms (PEComas) are rare soft tissue tumors arising around small blood vessels and can occur across multiple organs, including the lungs, gastrointestinal tract, kidneys, liver, and uterus.
• According to DelveInsight's estimates, the total incident cases of PEComa in the 7MM were approximately 408 in 2025.
• According to National Organization for Rare Disorders (NORD), there are more than 6 types of PEComa including angiomyolipomas (AMLs), clear cell sugar tumors, primary extrapulmonary sugar tumor (PEST), lymphangioleiomyomatosis (LAM), clear-cell myomelanocytic tumor (CCMT) of the falciform ligament/ligamentum teres, primary cutaneous PEComa (CCCMT-cutaneous clear cell myomelanocytic tumor), and PEComas not otherwise specified (NOS).
• The PEComas occur more frequently in females compared to males, indicating a notable gender skew in disease distribution.

Perivascular Epithelioid Cell Neoplasm (PEComa) Epidemiology Forecast in the 7MM

• 2025 Incident Cases of PEComa: ~408
• PEComa Growth Rate (2026-2036): 1.8% CAGR

DelveInsight's 'Perivascular Epithelioid Cell Neoplasm (PEComa) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the PEComa, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Perivascular Epithelioid Cell Neoplasm (PEComa) Understanding and Diagnosis Algorithm

Perivascular Epithelioid Cell Neoplasm (PEComa) Overview

Perivascular Epithelioid Cell Neoplasm is a rare mesenchymal tumor characterized by perivascular epithelioid cells with both melanocytic and smooth muscle features. It can occur in multiple organs (especially uterus, kidney, liver, retroperitoneum) and is sometimes linked to Tuberous Sclerosis Complex. Patients are often asymptomatic, but symptoms depend on tumor location and size. Diagnosis is based on histopathology and immunohistochemistry, with key markers including HMB-45, Melan-A, and smooth muscle actin, supported by imaging (CT/MRI). Behavior ranges from benign to malignant, so risk assessment is essential.

Perivascular Epithelioid Cell Neoplasm (PEComa) Diagnosis

Diagnosis of Perivascular Epithelioid Cell Neoplasm is primarily based on histopathological examination and immunohistochemistry. Tumor cells show characteristic perivascular epithelioid morphology and co-express melanocytic markers (HMB-45, Melan-A) and smooth muscle markers (smooth muscle actin). Imaging techniques (CT or MRI) help in identifying tumor location and extent, but definitive diagnosis requires biopsy. Assessment of features such as tumor size, necrosis, mitotic activity, and invasion is important to determine malignant potential.

Perivascular Epithelioid Cell Neoplasm (PEComa) Epidemiology

Key Findings from Perivascular Epithelioid Cell Neoplasm (PEComa) Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total prevalent cases of PEComa in the 7MM were approximately 408 in 2025.
• Among EU4 and the UK, Germany accounts for the highest incidence of PEComas, followed by France and the UK.
• In 2025, Perivascular Epithelioid Cell Neoplasm (PEComa) by stage in the US, benign tumor is the most prevalent subtype ~67% cases followed by local aggressive behavior (malignant PEComa) accounting for ~33% cases.
• The observed female predominance and earlier onset of PEComa highlight the importance of sex-specific screening and early intervention strategies, particularly in recognizing susceptibility patterns and addressing disease at onset to prevent long-term complications.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of PEComa, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

PEComa Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of PEComa ? What will be the growth opportunities across the 7MM concerning the patient population with PEComa ?
• What is the historical and forecasted PEComa patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.